AOD-9604 Peptide — Lipolytic Fragment Research Guide

AOD-9604 peptide is a modified fragment derived from human GH (hGH), specifically the lipolytic fragment corresponding to amino acids 176–191 of the human growth hormone molecule. Originally developed by Metabolic Pharmaceuticals, this aod 9604 peptide was designed to harness the fat-burning properties of growth hormone while eliminating the proliferative effects associated with full-length hGH. Six clinical trials were conducted investigating its effects on fat metabolism, body composition, and metabolic safety in human subjects, making it one of the more clinically studied growth hormone-derived peptides.

What Is AOD 9604? The Lipolytic Fragment of Human GH

AOD 9604 is a 16-amino-acid synthetic analog representing the C-terminal lipolytic fragment of human gh. Researchers identified this segment as the region responsible for hGH’s fat oxidation activity, separating it from the growth-promoting N-terminal domain. Unlike full-length growth hormone, the aod 9604 peptide does not bind the primary GH receptor with sufficient affinity to promote unwanted tissue growth, making it a focused research tool for studying fat metabolism without the metabolic complications of full hGH. Studies in obese mice demonstrated significant reductions in body fat through fat cell receptor-mediated lipolysis.

Fat Metabolism and Fat Burning Mechanisms

The primary research interest in aod 9604 centers on its fat burning properties. The peptide interacts with fat cell receptors to stimulate fat oxidation and inhibit lipogenesis—the conversion of carbohydrates into stored fat. Research in obese mice showed that chronic treatment with AOD 9604 reduced adipose tissue volume through enhanced adipose tissue metabolism without significant changes in circulating insulin or glucose. Fat cells treated with AOD 9604 exhibited increased lipolysis rates, measured through glycerol and free fatty acid release, confirming a direct fat metabolism mechanism at the cellular level.

Clinical Trials Overview: Six Clinical Trials Data

Six clinical trials were conducted on AOD 9604 in human subjects, making it unusual among peptide research compounds. These trials evaluated weight loss outcomes, lipid metabolism markers, and metabolic safety parameters across varied dose levels and treatment durations. Key findings from the clinical trials included dose-dependent body fat reductions in subjects with obesity and impaired glucose tolerance, with the placebo group showing no comparable changes. Importantly, safety data from these six clinical trials demonstrated no serious adverse events attributable to AOD 9604 at therapeutic doses studied, distinguishing it from compounds associated with significant metabolic dysfunction.

Growth Hormone and Insulin Resistance Research

A critical differentiating feature of aod 9604 compared to human growth hormone is its insulin resistance profile. Full-length growth hormone is associated with insulin resistance and impaired glucose tolerance at pharmacological doses. In contrast, clinical trials of AOD 9604 did not reveal significant insulin sensitivity impairment, and some data suggested mild improvements in insulin sensitivity parameters compared to placebo group controls. Lipid metabolism markers including triglycerides and LDL cholesterol were also monitored across clinical trial cohorts, with the aod 9604 peptide showing a neutral-to-favorable lipid metabolism profile at doses studied.

Obese Mice and Preclinical Fat Cell Research

Before the six clinical trials, foundational research in obese mice established aod 9604’s fat burning credentials. In diet-induced obesity models, chronic treatment reduced body weight and improved body composition improvement metrics compared to untreated controls. Fat cell receptor binding studies using radiolabeled AOD 9604 confirmed that the peptide achieves its fat oxidation effects through a receptor-mediated pathway distinct from the classical growth hormone receptor. These obese mice studies informed the dose selection and safety monitoring frameworks used in subsequent human clinical trials.

Lipid Metabolism and Body Composition Improvement

Beyond direct fat burning, aod 9604 research has examined broader lipid metabolism effects. Studies measuring adipose tissue metabolism in cell culture and animal models showed changes in fatty acid synthase activity and hormone-sensitive lipase expression—enzymes central to lipid metabolism regulation. Body composition improvement outcomes in clinical subjects, measured by DEXA scanning and waist circumference, correlated with these biochemical lipid metabolism changes. Researchers also documented body weight stabilization in some chronic treatment cohorts even after AOD 9604 discontinuation, suggesting durable body composition effects. Available for research from Iron Peak Peptides.

FDA Approved Status and Regulatory Considerations

Despite six clinical trials and an extensive safety data package, AOD-9604 has not achieved FDA approved status for any therapeutic indication. Metabolic Pharmaceuticals pursued regulatory approval for an obesity indication, but development was not completed. The compound does hold GRAS (Generally Recognized As Safe) designation from the FDA for use as a food ingredient at specified levels, which reflects the favorable safety data accumulated across clinical trials. This regulatory context distinguishes aod 9604 peptide from experimental compounds lacking any regulatory review history.

Peptide Therapy Research Context

Within the broader peptide therapy research landscape, aod 9604 represents an important case study in fragment-based peptide design. The strategy of isolating functional domains from larger protein hormones to create focused, safer research tools has informed subsequent peptide development programs. Researchers studying peptide therapy mechanisms use aod 9604 as a model compound for understanding how lipolytic signaling can be decoupled from anabolic signaling in growth hormone biology. Health history screening protocols in clinical trials also provide a framework for safe research subject enrollment in peptide therapy studies.

Potential Side Effects Observed in Research

The potential side effects profile of aod 9604 peptide, as observed across preclinical and clinical research, has been notably mild. In six clinical trials, injection site reactions and transient nausea were the most commonly reported events. No serious adverse events were attributed to aod 9604 at doses studied in clinical settings. Unlike full human gh, no insulin resistance, fluid retention, or joint pain signals emerged from the clinical trial safety databases. These side effects findings distinguish aod 9604 from broader growth hormone research, where metabolic side effects are a consistent concern.

Research Use Only

All content on this page is strictly for scientific research purposes. AOD-9604 peptide is not approved for human therapeutic use, is not a drug or dietary supplement, and should be used only by qualified researchers in appropriate laboratory settings. Nothing here constitutes medical advice, dosage guidance, or treatment recommendations.